Can Solid Biosciences Challenge Sarepta in the DMD Market?

When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations cause it, and the condition progressively gets worse over time. Solid Biosciences TodaySLDBSolid Biosciences$2.94 -0.18 (-5.77%) 52-Week Range$2.77▼$12.32Price Target$15.67Add to WatchlistCurrently, the only Food and Drug Administration (FDA)-approved gene therapy to treat DMD is ELEVIDYS. Biotech company Sarepta Ther ...